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Abstract
Background: Hematopoietic stem cells (HSC), in particular mobilized peripheral blood stem cells, represent an attractive
target for cell and gene therapy. Efficient gene delivery into these target cells without compromising self-renewal and multi-
potency is crucial for the success of gene therapy. We investigated factors involved in the ex vivo transduction of CD34
+
HSCs in order to develop a clinically relevant transduction protocol for gene delivery. Specifically sought was a protocol that
allows for efficient transduction with minimal ex vivo manipulation without serum or other reagents of animal origin.
Methodology/Principal Findings: Using commercially available G-CSF mobilized peripheral blood (PB) CD34
+ cells as the
most clinically relevant target, we systematically examined factors including the use of serum, cytokine combinations, pre-
stimulation time, multiplicity of infection (MOI), transduction duration and the use of spinoculation and/or retronectin. A
self-inactivating lentiviral vector (SIN-LV) carrying enhanced green fluorescent protein (GFP) was used as the gene delivery
vehicle. HSCs were monitored for transduction efficiency, surface marker expression and cellular function. We were able to
demonstrate that efficient gene transduction can be achieved with minimal ex vivo manipulation while maintaining the
cellular function of transduced HSCs without serum or other reagents of animal origin.
Conclusions/Significance: This study helps to better define factors relevant towards developing a standard clinical protocol
for the delivery of SIN-LV into CD34
+ cells.
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Introduction
Gene therapy holds promise for the cure of various inherited
and acquired diseases, as evidenced by the success in the treatment
of X-linked severe combined immunodeficiency (SCID-X1) [1],
adenosine deaminase (ADA) deficiency [2] and chronic granulo-
matous disease (CGD) [3]. HSCs are potential targets for many
applications of gene delivery, owing to their ability to differentiate
into all lineages of the hematopoietic system [4]. HSCs can
theoretically maintain the supply of gene-transduced hematopoi-
etic cells throughout a patient’s lifespan. Efficient gene delivery
into target cells and the maintenance of the biological functions of
these cells are therefore crucial to the success of gene therapy.
Various sources of HSCs have been used in research and
clinical studies including cord blood (CB), adult bone marrow
(BM) and mobilized peripheral blood (PB) HSCs. Although CB
HSCs are relatively easier to manipulate in vitro, harbor a higher
proliferative capacity and are more susceptible to gene transduc-
tion [5,6], adult HSCs are more therapeutically relevant for
human gene therapy applications. In particular, granulocyte
colony-stimulating factor (G-CSF) mobilized PB stem cells have
become the major source of HSC transplantation [7].
Prolonged ex vivo manipulation induces entry into the cell cycle
resulting in proliferation. This has, in many cases, been shown to
decrease the frequency of primitive HSCs in culture and
compromise their long-term repopulating ability [8,9]. Cytokine
stimulation of quiescent stem cells prior to transduction aims to
induce cell cycling and is an essential requirement for oncore-
troviral integration [10,11]. Although preclinical studies in murine
models have shown pre-stimulation can improve the transduction
efficiency of reconstituting stem cells, such manipulation can also
induce differentiation of HSCs and thereby lead to the loss of their
reconstitution ability [8,12]. Lentiviruses have been shown to
transduce both proliferating and non-proliferating cells and are
therefore capable of infecting certain types of quiescent cells [13].
This provides the potential to reduce ex vivo manipulation of the
target cells with the aim of preserving their cellular functions.
Although efficient lentiviral transduction of human HSCs may not
necessarily require proliferation itself, cytokine stimulation to
activate the cells to enter cell cycle may improve their susceptibility
to transduction [14,15]. Improved safety features, such as self
inactivating long terminal repeats (SIN-LTRs) and minimal split
packaging designs, has led the SIN-LV to become the clinical
vector of choice by many researchers. This growing confidence is
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6461reflected by the approval for trials using SIN-LV by both the
European and American regulatory authorities [16,17].
Reagents of animal origin, in particular fetal bovine serum
(FBS), are commonly used in primary cell culture for both research
and clinical trials, particularly in retroviral gene therapy
applications [1,2,18]. However, there are a number of potential
issues regarding safety and efficacy with the use of these reagents.
Serum containing medium has been shown to induce/accelerate
differentiation of HSCs thereby reducing their multi-potency.
Reagents of animal origin also have the potential to induce
immunological reactions, may contain adventitious agents and/or
harbor the potential risk of prion disease [19–21]. For these
reasons, it is preferable that ex vivo manipulation of human HSCs
for clinical application be carried out in the absence of animal
products.
Currently, there is great variation among research and clinical
groups regarding optimal transduction conditions for efficient
lentiviral gene delivery into target HSCs [6,22–25]. In this study,
we aim to systematically investigate factors involved in the ex vivo
transduction of CD34
+ (G-CSF) mobilized PB HSCs and
contribute to the development of a clinically relevant transduction
protocol.
Materials and Methods
Cells and Cell Culture
Human primary G-CSF mobilized peripheral blood CD34
+
cells (cryopreserved) were obtained from either Lonza (Basel,
Switzerland) or StemCell Technologies (Vancouver, BC, Canada).
Briefly, mononuclear cells were obtained from a peripheral blood
collected through apheresis. CD34+ cells were then isolated from
the MNC population by positive selection using immunomagnetic
cell separation procedures. Cells were cryopreserved in a 1.8 ml
solution of 50% IMDM, 40% FBS, 10% DMSO (0.2 mm filtered),
and shipped on dry ice. All recombinant human cytokines used in
primary cell culture, including stem cell factor (SCF), thrombo-
poietin (TPO), flt3/flk2 ligand (Flt3L) and interleukin-3 (IL-3)
were obtained from R&D Systems (Minneapolis, MN, USA).
Unless otherwise stated, a standard cytokine mix of SCF, Flt3L
and TPO at 50 ng/ml each was used. Various culture media were
used, including IMDM (Gibco/Invitrogen, Carlsbad, CA, USA),
X-vivo 10 (Lonza, Basel, Switzerland), Stemline (Sigma, St. Louis,
MO, USA), Stemline II (Sigma, St. Louis, MO, USA), StemSpan
(StemCell Technologies, Vancouver, BC, Canada), HPMG
(Cambrex/Lonza, Basel, Switzerland), and CellGro-SCGM (Cell-
Genix, Freiburg, Germany).
Lentivirus Production and Titre
A four-plasmid self-inactivating lentiviral vector system was
obtained from Cell Genesys (San Francisco, CA, USA). A transfer
vector encoding enhanced green fluorescent protein (pKC.MND-
eGFP-neo) was used throughout this study (Figure 1A). GFP,
which can be qualitatively and quantitatively measured by flow
cytometry, was used as a surrogate in the study as an objective
reflection of cells containing the transgene. GFP has estimated
half-life of .24 hours [26], exhibiting a high resistance to heat,
pH, detergents, organic solvents, and most common proteases
[27–30]. The stability and ease of detection makes GFP an
efficient tool to measure gene marking. Lentivirus was produced in
293AAV cells (Cell Genesys) via calcium phosphate transfection of
the plasmids pKC.MND-eGFP-neo; pKgagpol (Gag-Pol); pKrev
(Rev) and pK.G (VSVG envelope) at a ratio of mass of 20:13:5:7
Figure 1. Lentiviral vector and transduction procedures. (A) Schematic diagram of Cell Genesys SIN lentiviral transfer vector
pKC.MND.eGFP.neo. CMV 59 LTR: modified cytomegalovirus 59 long terminal repeat; RRE: rev response element; cPPT/CTS: central polypurine
tract/central termination sequence; MND: myeloid proliferative sarcoma virus promoter; eGFP: enhanced green fluorescent protein; SV40: simian virus
40 promoter; neo: neomycin resistance gene; WPRE: woodchuck post translational regulatory element; DU3 LTR: modified U3 long terminal repeat.
(B) Schematic diagram of experimental procedures for CD34
+ transduction. Cells were pre-stimulated for 48, 24 or 4 h prior to transduction at T0 at
various MOIs, with and without retronectin and/or spinoculation. Virus was washed from the cells 2, 6, 24 or 48 h post transduction, placed back into
culture and analysed by flow cytometry 48 h post transduction.
doi:10.1371/journal.pone.0006461.g001
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6/T225 flask and
cultured overnight. The next day cells were transfected in the
presence of 10% FBS with 30 mg of transfer vector plasmid and
37.5 mg of packaging mix (19.5 mg Gag-Pol; 7.5 mg Rev; 10.5 mg
VSVG). Media was removed 4 h post transfection, cells rinsed and
serum free media added. Virus was harvested 24 h later,
centrifuged and filtered through 0.2 mm pore size. Virus was
harvested in serum free X-vivo 10 unless otherwise stated. Viral
titre was determined by transduction of HT1080 cells with 4-fold
serial dilutions of VCM (neat to 1/4096) in a 96-well format in
triplicate. 72 h post transduction, cells were detached with trypsin
and transferred to a 96-well non-tissue culture treated plate for
FACS analysis of GFP expression. Viral titre (ivp/ml) was
calculated using the percentage of GFP expressing HT1080 cells
using the formula as follow: Titre (ivp/ml) equals to (cell
number6percentage of GFP
+ cells6Dilution factor) divided by
VCM volume (ml) [31].
Primary CD34
+ Cell Culture, Transduction and FACS
Analysis
CD34
+ cells were thawed, counted, assessed for viability and
seeded at 0.5 to 2610
5 cells/ml in various culture media (as
specified in each experiment). Media was supplemented with a
number of cytokine combinations including SCF, Flt3L, TPO and
IL-3 at different concentrations (as specified in results). Following
cytokine pre-stimulation for 4, 24 or 48 h, cells were transduced
with a GFP-encoding lentivirus under a number of different
conditions: with or without retronectin (5 mg/cm
2) (Takara Shuzo,
Shiga, Japan), with or without spinoculation (600 g for 1 h, 30uC),
at various multiplicity of infection (MOI) and differing transduc-
tion durations. Cells were harvested 48 h post transduction for
FACS analysis. GFP and cell surface marker expression were
determined using a FACSCanto II with FACSDiva software (BD
Biosciences, San Jose, CA, USA). Transduction efficiency was
estimated as the percentage of GFP positive cells. The panel of
surface markers used to assess the differentiation state of CD34
+
cells in culture included CD34, CD38, CD90, CD117, CD135
(BD Biosciences) and CD133 (Miltenyi Biotec, Bergisch Gladbach,
Germany). An Aldefluor kit (StemCell Technologies, Vancouver,
BC, Canada) was used to measure aldehyde dehydrogenase
activity, another marker for HSCs. CountBright beads (Invitrogen,
Carlsbad, CA, USA) were added to each FACS tube to allow the
estimation of cell concentration. Unless otherwise stated, each
experiment was performed with three biological replicates for each
condition and FACS analysis for GFP and CD34 expression only
was performed in duplicate for each replicate. A summary of
experimental procedures is shown in Figure 1B.
Clonogenic Assay
The clonogenic activities of CD34
+ cells were assessed following
lentiviral transduction. Cells were plated at 1610
3/ml in 1%
methylcellulose supplemented with SCF 50 ng/ml, GM-CSF
10 ng/ml, IL-3 10 ng/ml and erythropoietin 3 U/ml (Methocult
H4434, StemCell Technologies). Granulocyte-macrophage colo-
ny-forming units (CFU-GM), erythroid burst-forming units/
cluster-forming units (BFU-E/CFU-E), and granulocyte, erythro-
cyte, megakaryocyte and macrophage colony-forming units (CFU-
GEMM) consisting of more than 40 cells were scored at days 10
to 14.
Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 5
software. Data sets were analysed for statistical significance by
One-way ANOVA followed by post hoc Tukey test or Mann-
Whitney two tailed test, unless otherwise stated. Results are
presented as mean6SD (standard deviation).
Results
Comparison of CD34
+ Cell Growth, Differentiation and
Transduction in Serum-containing versus Serum-free
Media
Several serum-free culture media designed for HSCs were tested
for their ability to support CD34
+ growth, maintain multi-potency
and to allow efficient gene delivery via lentiviral transduction.
Cryopreserved G-CSF mobilized PB CD34
+ cells were thawed
and seeded at 1-2610
5cells/ml in various serum free media
supplemented with a combination of cytokines, either as recom-
mended by the manufacturer or a ‘‘standard’’ cytokine combina-
tion used in our laboratory (SCF, Flt3L and TPO, each at 50 ng/
ml). IMDM with 10% FBS, a standard culture medium for
primary CD34
+ cells, was used as the serum-containing control.
CD34
+ cells were assessed via FACS analysis at day 4 and/or day
7 for cell expansion using counting beads and the differentiation
status of the cells was determined by the expression of various
primitive markers (CD34, CD38, CD133, CD90, CD135,
CD117). Aldehyde dehydrogenase, the expression of which is
elevated in primitive cells [32–34], was also assessed. In general, it
was observed that CD38 expression was markedly higher in
serum-containing cultures compared to serum-free conditions,
possibly due to the presence of retinoids in serum which have been
shown to induce CD38 expression [35,36]. Therefore, the
comparison of CD38 expression in serum versus serum-free
conditions may not reflect the true maturation state of the cells.
The measurement of surface expression of CD135 (Flt3 receptor)
and CD117 (c-Kit receptor) was also hampered by internalization
of the receptors due to the presence of ligands (Flt3L and SCF) in
the culture medium. As such, the expression of CD38, CD135 and
CD117 was not analysed in these experiments. Overall, there were
no marked differences observed in terms of growth and differ-
entiation between the various culture media assessed. Likewise, the
expansion of CD34
+ cells was not markedly different between the
media tested, with the exception of CellGro, which resulted in
lower expansion over the 4-day culture period (Figure 2A). Cell
viability was also similar across all culture conditions with no
significant differences found when compared to the serum
containing media, except for Stemspan which yielded a much
lower viability of around 40% (Figure 2A). The expression levels of
the primitive markers CD34 and CD133 remained similar when
cultured in either serum-free or serum-containing media
(Figure 2B), although a decrease in CD34 expression was seen
for cells cultured in serum containing media after 7 days (72% in
the presence of serum versus an average of 98% in serum-free
media, data not shown). CD90 expression however, demonstrated
a significant decrease when cultured in Stemline and X-Vivo. The
prevalence of double positive CD34
bright/aldefluor
+ cells was
reduced to 15% in serum-containing medium, as compared to 36–
62% in serum-free cultures. No marked difference in aldehyde
dehydrogenase activity was observed after 4 days in culture
(Figure 2C). By day 7 however, the activity decreased to an
average of 50% in serum-containing cultures as wells as in two of
the serum-free cultures (HGPM and X-vivo 10), but remained
high in Stemline (80%) and CellGro (89%). This is not of primary
concern as a clinical transduction protocol is unlikely to be longer
than 4 days.
The ability of serum free media to support efficient lentiviral
transduction was also tested. CD34
+ cells were pre-stimulated for
Lentiviral Transduction of HSC
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medium (IMDM+10% FBS) supplemented with either a triple
cytokine combination (SCF, TPO and Flt3L all at 50 ng/ml) or a
combination of two cytokines as previously used in a phase II
retroviral/CD34
+ clinical trial by this group (SCF 50 ng/ml and
TPO at 100 ng/ml) (manuscript submitted). Cells were transduced
on retronectin coated plates (5 mg/cm
2) at an MOI of 9 and
transduction efficiency was assessed via GFP expression 48 h post
transduction. Overall, a higher level of transduction was seen in
serum free cultures: 24.861.0% in serum-free versus 17.161.5%
in serum containing media in the presence of two cytokines
(p,0.05); and 2260.6% in serum-free versus 19.260.8% in serum
containing media with the triple combination (p.0.05)
(Figure 2D). While the mean fluorescence intensity (MFI) of
GFP expression was slightly higher in cells cultured in serum
containing media (data not shown), the loss of expression of the
primitive marker CD34 observed under serum containing
conditions with the triple combination was greater (95.8% in
serum-free versus 85.6% in the presence of serum, data not
shown).
Comparison of Lentiviral Transduction in Stemline II and
X-vivo 10 Serum-free Media
Two serum free media, X-vivo 10 and Stemline II, were chosen
for further assessment based on the need for serum-free and
animal origin-free reagents, availability of GMP grade products for
clinical application and pre-existing data. Stemline II was selected
over Stemline due to the manufacturer’s claims of a high capacity
for the maintenance and expansion of both early (CD34
+/CD38
2)
and late (CD34
+/CD38
+) progenitor cells.
CD34
+ cells were pre-stimulated for 48 h, in either X-vivo 10
or Stemline II, in the presence of various cytokine combinations
Figure 2. Comparison of CD34
+ cell growth, differentiation and transduction in serum vs serum-free media. (A) Cell expansion and
viability after 4 days in culture in various media. Data collated from independent experiments (n=3 for IMDM/FBS, Stemline and X-vivo 10; n=2 for
HPGM and CellGro; n=1 for Stemspan), and normalized to IMDM/FBS control. (B) Expression of primitive markers after 4 days in culture in various
media. Data collated from independent experiments (n=3 for IMDM/FBS, Stemline and X-vivo 10; n=2 for HPGM and CellGro; n=1 for Stemspan).
(C) Aldehyde dehydrogenase expression expressed as the percentage of aldefluor positive cells on days 4 and 7 of culture in various media. (D)
Comparison of transduction efficiency in serum vs serum-free media supplemented with various cytokine combinations. * p,0.05, when comparing
serum-free/SCF+TPO to its serum containing counterpart. nd=not determined on data sets where n#2.
doi:10.1371/journal.pone.0006461.g002
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each at 50 ng/ml). Cells were then transduced with virus
containing media (VCM) containing GFP lentivirus harvested
in either X-vivo 10 or Stemline II at an MOI of 9. Transduction
was performed on retronectin coated plates via spinoculation.
Cells were analyzed by FACS analysis for EGFP expression and
cell surface marker expression 48 h post transduction. A higher
percentage of transduction was seen in cultures supplemented
with the triple cytokine combination as compared to any
combination of two (p,0.05), irrespective of the basal media
(Figure 3A). This was especially evident in the Stemline II
cultures, in which both the transduction efficiency and the MFI of
GFP expression was significantly increased with the triple
cytokine combination (p,0.05 compared to X-vivo 10)
(Figure 3A). Although a higher percentage of transduction was
observed in Stemline II cultures, X-vivo 10 appeared to be more
robust as less fluctuation in the overall performance of the cells
(transduction efficiency and viability) was seen when supported
with various cytokine combinations (Figure 3A). The triple
cytokine combination also resulted in increased cell numbers
(expressed as fold expansion from input cells) in both culture
media, while viability remained consistently above 60% across
the majority of the culture conditions. The exception was
Stemline II supplemented with SCF and Flt3L or Flt3L and
TPO combinations, both of which were shown to have viabi-
lities below 30% in one experiment (Figure 3B). No significant
difference was observed in the expression of cell surface markers
between the various culture conditions with the majority of cells
remaining CD34 positive after 96 h in culture (84.4% to 97.4%,
data not shown).
X-vivo 10 was chosen for further optimization because of the
consistent cell viability and transduction observed with the
different media and, unless stated otherwise, was used in all
subsequent experiments supplemented with the triple cytokine
combination.
Optimization of Transduction
Pre-stimulation. Although lentiviruses can transduce both
dividing and non-diving cells, several studies have indicated that
cytokine pre-stimulation improves the efficiency of lentiviral gene
transfer [14,15]. CD34
+ cells were pre-stimulated for 4, 24 or 48 h
in X-vivo 10 supplemented with the triple cytokine combination.
Transduction was carried out on retronectin coated plates using
spinoculation at an MOI of 9. Transduction efficiency and the
expression of cell surface markers were analyzed 48 h post
transduction as in previous experiments. As shown in Figure 4A,
transduction efficiency significantly increased (p,0.05 for all
combinations) with an increase in pre-stimulation time, both in
terms of the percentage of cells transduced and MFI of GFP in the
transduced cells. However, the increase in cell expansion in
relation to increased pre-stimulation time was not statistically
significant (2.760.9-fold for 48 h; 2.360.3-fold for 24 h; 1.160.1-
fold for 4 h) (Figure 4B). No differences were observed in the levels
of CD34 expression between the pre-stimulation times however,
CD133 and CD90 expression was significantly decreased
following 24 h and 48 h pre-stimulation (Figure 4C–E). It was
determined that 24 h pre-stimulation provided a suitable
compromise for pre-stimulation time and transduction efficiency
and was used in subsequent experiments.
Facilitation of Transduction: Spinoculation and/or Re-
tronectin. The necessity for the use of retronectin and spinocu-
lation to facilitate transduction was assessed to further streamline the
transduction protocol for possible clinical application. Following
24 h pre-stimulation (X-vivo 10, triple cytokine combination),
CD34
+ cells were transduced on retronectin coated plates (5 mg/
cm
2) or tissue culture treated plates with and without spinoculation.
As shown in Figure 5A, significant differences were observed
between all methods tested (p,0.05). Retronectin combined with
spinoculation resulted in the highest transduction efficiency both in
terms of the percentage of cells transduced (34.160.5%) and MFI of
GFP expression in the transduced cells. Transduction using
retronectin alone resulted in 24.661.3% transduction. There was
no advantage seen with spinoculation alone as the transduction
efficiencywascomparabletothetransductionlevelsof10%achieved
in the untreated tissue culture plate and spinoculation was not
investigated further.
Multiplicity of Infection. The effect of increasing the MOI
on transduction of CD34
+ cells was assessed. Cells were pre-
stimulated for 24 h and transduced on retronectin coated plates
using 2-fold serial dilutions of VCM resulting in MOIs ranging
from 2 to 12. When analysed 48 h post transduction, an increase
in the percentage of cells transduced correlated well (R
2=0.9655)
with the increase in MOI (Figure 5B). This was accompanied by
an increase in the MFI of GFP expression (data not shown),
suggesting an increase in the amount of GFP produced by the
Figure 3. Transduction efficiency of CD34
+ cells in X-vivo 10
versus Stemline II serum-free media in various cytokine
combinations. (A) Transduction efficiency in the CD34
+ cell
population. * p,0.05, when comparing Stemline II/triple cytokines to
X-vivo 10/triple cytokines (B) Cell expansion and viability following
transduction.
doi:10.1371/journal.pone.0006461.g003
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cells transduced with higher MOIs.
Transduction Duration. The duration of time for which
cells are exposed to virus was also investigated. CD34
+ cells were
transduced on retronectin coated plates using an MOI of 5
following 24 h pre-stimulation. The cells were cultured in VCM
for 2, 6, 24 and 48 h, after which time the cells were washed and
put back into culture in fresh growth medium. Transdution
efficiency was analyzed 48 h post initiation of transduction. The
percentage of transduced cells was found to increase significantly
with a longer transduction duration, with 18.860.4% of cells
expressing GFP following 48 h transduction and just over 1% for
2 h transduction (p,0.05, Figure 5C). Despite the increase in the
percentage of cells transduced, the MFI remained similar for the 2,
6 and 24 h transductions, with a significant increase seen only for
the cells transduced for the 48 h time period (p,0.05 when
comparing 48 h time period to 2 h, 6 h and 24 h, Figure 5D).
This suggests the possibility of a higher copy number per cell
occurring with a transduction period longer than 24 h.
Comparison of CD34
+ Cell Growth and Transduction with
Various Cytokine Combinations
Six different combinations of cytokines previously reported [1–
3,24,25] were tested as shown in Figure 6A. CD34
+ cells were
cultured and transduced in these cytokine combinations under
standard conditions (24 h prestimulation, 48 h transduction on
retronectin coated plates) at an MOI of 9 and analysed for GFP
and surface marker expression 48 h post transduction. Trans-
duced cells were then plated into methylcellulose cultures to
measure the effects of each cytokine combination on the
clonogenic capacity of the cells. Similar levels of transduction
were seen with all combinations (ranging from 23.7% to 28.6%)
with the exception of the IL-3 containing cytokine mix, in which
transduction was significantly higher at 53.461.2% (Figure 6B).
Figure 4. Effects of 4, 24 or 48 h pre-stimulation on CD34
+ cell transduction, growth and differentiation. (A) Transduction efficiency
48 h post transduction. (B) Expansion of CD34
+ cells post transduction. (C)–(E) Expression of primitive markers 48 h post transduction, (C) CD34, (D)
CD133 and (E) CD90. * p,0.05, when all combinations compared.
doi:10.1371/journal.pone.0006461.g004
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culture was accompanied by a slight decrease in CD34 expression
along with an increased total cell number as compared to all other
cytokine combinations (0.56610
6 for the IL-3 containing culture
compared to 0.20–0.25610
6 for all other conditions, data not
shown). No marked difference in cell viability was observed
between the conditions. Although the addition of IL-3 increased
the transduction level, it may negatively act to induce cell
differentiation ex vivo, thereby reducing the multi-potency of the
CD34
+ cells. Interestingly, increased cytokine concentrations (up
to 300 ng/ml for SCF and Flt3L; 100 ng/ml for TPO) did not
provide any advantage over the low concentration conditions
(10 ng/ml SCF, Flt3L and TPO) in terms of either transduction
(Figure 6B) or clonogenic activity of the cells, determined as total
colony number and ratio of different types of colonies (Figure 6C).
Discussion
Gene therapy is a relatively new therapeutic approach with
early stage clinical development still under investigation. As such,
no standard procedures exist regarding target cell ex vivo
manipulation. Research and/or clinical applications have used a
wide variety of culture components and protocols. Safety and
efficacy are of primary concern with such cell therapies and some
current trials are incorporating the use of serum-free culture
conditions for the ex vivo manipulation of HSCs. This study
provides a systematic investigation into parameters involved in ex
vivo culture and transduction of CD34
+ HSCs for the development
of a clinically relevant protocol.
Vector design is continually being improved to address serious
safety concerns such as insertional oncogenesis and the
generation of replication competent virus. Murine leukemia virus
(MLV)–based gammaretroviral vectors and human immunodefi-
ciency virus (HIV)–based lentiviral vectors are the two most
commonly used retroviral vector systems used in gene therapy.
Theoretically, both of these integrative viral vectors may trigger
oncogenesis as a consequence of insertional mutagenesis, as
shown in early clinical trials in which gamma-retrovirus caused
overt leukemia in some patients [37–39]. More recent integration
studies from various groups have demonstrated a clear difference
Figure 5. Assessment of CD34
+ transduction methods and duration. (A) Transduction efficiency using retronectin and/or spinoculation. RN/
Spin; retronectin and spinoculation; RN: retronectin only; Spin; spinoculation only; none: no retronecin or spinoculation. * p,0.05, when all
combinations compared. (B) Transduction efficiency and GFP expression levels of cells transduced with a range of MOIs (0, 2, 4, 6, 8, 10, 12),
R
2=0.9655 (Pearson Correlation). (C) & (D) Effects of transduction duration on efficiency. (C) Transduction efficiency, * p,0.05 for all combinations
and (D) GFP expression of transduced cells following various transduction durations (2, 6, 24 and 48 h). * p,0.05, when 2, 6 and 21 h are compared
to 48 h.
doi:10.1371/journal.pone.0006461.g005
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While gamma-retrovirus demonstrates a bias towards integrating
near transcription start sites and certain cell-cycle genes and
oncogenes, the HIV-based Lentivirus tends to integrate prefer-
entially within highly expressed genes [40–44]. For these reasons
it is speculated that the retroviral system may be more prone to
adverse gene activation, and such gene activation results from the
activation of the downstream genes by the long terminal repeats
(LTRs) within these vectors [45,46]. A recent study by Montini et
al. identified the transcriptionally active LTR as the major
determinant of genotoxicity and validated the improved safety
conferred by SIN LTR design [47]. For these reasons, vectors
now incorporate self-inactivating LTRs (SIN-LTRs), thereby
reducing the potential for promoter activation [48]. Another
great safety concern for clinical gene therapy application is the
potential for the production of replication competent retrovirus/
lentivirus (RCR/RCL). As the production of RCR/RCL is
believed to occur through homologous recombination between
overlapping sequences, the functional components of the viral
genomes are divided onto separate expression plasmids to
minimize this risk [49,50]. These new split-function packaging
designs are inherently safer as multiple, ordered recombination
events would be required to generate a replication competent
virus. These improved safety features often make lentivirus the
preferred vehicle for clinical gene therapy by many researchers
and may become the new standard acceptable by regulatory
authorities in the near future. Currently, several clinical trials
employing lentiviral vectors, including a triple therapy for the
treatment of HIV have been approved by FDA (collaborative
study between Benitec and the City of Hope, 16), and an
adrenoleukodystrophy (ALD) trial by EMEA (European Medic-
inal Agency, 17).
We demonstrated that a SIN lentiviral vector can readily
transduce G-CSF mobilized PB CD34
+ cells with minimal ex vivo
manipulation under serum-free culture conditions, without
altering their proliferation potential or ability to maintain multi-
lineage differentiation. The removal of FBS from cell culture
eliminates the safety concerns associated with the use of such
products and provides for a more consistent outcome by removing
likely batch variations in FBS. Serum-free culture conditions have
been increasingly used for clinical gene transfer [3,54] and our
results demonstrate that serum-free culture does not impair
CD34
+ cell survival or growth in vitro and maintains the
primitiveness of these cells as measured by aldehyde dehydroge-
nase expression. This study also demonstrates that serum-free
culture supports lentiviral gene delivery into primary cells as well
as, if not better, than serum containing media. This is further
evidence to support the use of serum-free ex vivo culture as a
practical approach for gene therapy applications.
To maintain the biological function of HSCs, namely self-
renewal and multipotency, minimizing ex vivo manipulation by
reducing culture time and the concentration of stimulatory
cytokines in the culture media is an important step. Minimal
cytokine stimulation of HSCs may help preserve stem cell function
and provide for the effective ‘‘activation’’ of stem cells that renders
them susceptible to transduction. Although other reports demon-
strate transduction of human CD34
+ cells in the absence of
cytokine pre-stimulation, increased levels of gene transfer were
consistently observed if the cells were cultured with well-defined
cytokines [55,56]. A recent study has shown that proteasome
activity, which limits the efficiency of HSC transduction by
lentiviral vectors, is down-regulated in hematopoietic progenitors
by cytokine prestimulation [57]. In our study, although higher
transduction was achieved following 48 h pre-stimulation, the
corresponding decrease in the surface expression of CD90 and
CD133 indicates a loss of primitivity. Four hour pre-stimulation
on the other hand, demonstrated substantially reduced transduc-
tion, more than two fold lower than 48 h pre-stimulated cells, yet
surface expression of primitive markers remained relatively high.
Interestingly, our data also showed that higher cytokine concen-
trations do not provide for improved transduction efficiency over
that achieved with just 10 ng/ml of SCF, Flt3L and TPO. It must
be considered that the experiments in this report were performed
with cryopreserved and not fresh HSCs which would be the likely
target cells for gene delivery in clinical setting. It remains possible
that efficient transduction may be achieved with short (4 h) to no
pre-stimulation in a low concentration (10 ng/ml) of cytokines in
freshly isolated HSCs, and this warrants further testing in clinical
studies. While an assessment of the bone marrow repopulation
capacity of transduced cells would be invaluable in evaluation of
the preservation of biological function of HSCs, the inherent lack
Figure 6. Comparison of CD34
+ cell growth and transduction
with various cytokine combinations. (A) Cytokine combinations
used, ng/mL (B) Transduction efficiency in various cytokine combina-
tions. * p,0.05, when compared to all other cytokine combinations (C)
Clonogenic potential. Mock: non-transduced cells; Txd: transduced cells;
C/BFU-E: Colony/blast forming units – erythroid; CFU-GM: Colony
forming unit – granulocyte/macrophage; CFU-GEMM: Colony forming
unit – granuloycte, erythroid, macrophage, megakaryocyte.
doi:10.1371/journal.pone.0006461.g006
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human hematopoietic reconstitution, may have limited biological
relevance for therapies targeting the T-cell Lineage.
It has been demonstrated that the MOI at the time of
transduction closely correlates with the copy number in target
cells [58,59]. Transduction of HSCs using a low MOI to achieve a
low copy number per cell is preferable for clinical trial protocols to
minimize the risk of insertional mutagenesis. In the present study,
we demonstrated that transduction correlated with MOI, both in
terms of the percentage of cells transduced and the MFI of GFP
expression in transduced cells. This supports previous studies to
indicate that an increased MOI may increase the total number of
transduced cells but also increase the number of integrated copies
per cell. Other studies have shown that lentiviral vectors
transiently arrest transduced cells when used at high concentra-
tions and resulted in a marked decrease in the growth rate of the
cells [60,61]. The lack of observed differences in cell growth and
viability in our study may be explained by the relatively low range
of MOI (between 2 to 12, due to the limitations of cell number and
viral titre) used throughout the study, which is markedly lower
than those reported by some other groups [24,25,62]. Another
important factor to be taken into consideration is the duration in
which the cells are in contact with the virus. The time frame
should be long enough to enable infection of a maximum number
of cells, however, prolonged exposure may cause unwanted
cellular toxicity and may also increase the chance of multiple
integrations [63,64]. From our observations, the percentage of
transduced cells increased with an increase in exposure time, but
the MFI of GFP expression in the transduced cells remained
similar for exposures of up to 24 h. However, transduction times
as long as 48 h not only resulted in an increased percentage of
marked cells, but also exhibited an increase in MFI, indicating a
possible increase in target cell copy number. The use of low MOIs
combined with a shorter virus exposure times of up to 24 h may
therefore be preferable for transduction conditions for clinical
protocols.
In summary, our study investigated the possibility of minimizing
the ex vivo manipulation of primary CD34
+ cells for use in clinical
applications with the primary aim of maintaining safety and
efficacy. Critical parameters, such as culture conditions free of
serum and other products of animal origin, pre-stimulation and
cytokine combinations, transduction, MOI and virus exposure
period were assessed. Our study supports the practicality of using a
transduction protocol that employs short to no pre-stimulation
with low cytokine concentrations, low MOI and short virus
exposure times under serum-free culture conditions. Further
detailed analysis of integrated viral copy number and evaluation
of transduction protocols would be required in the context of the
intended clinical application along with functionality testing for
the transduced cells.
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